Oppenheimer Asset Management Inc. Purchases 6,708 Shares of Global X Genomics & Biotechnology ETF $GNOM

Oppenheimer Asset Management Inc. increased its position in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) by 8.1% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 89,631 shares of the company’s stock after purchasing an additional 6,708 shares during the quarter. Oppenheimer Asset Management Inc. owned approximately 1.79% of Global X Genomics & Biotechnology ETF worth $756,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of GNOM. Oxinas Partners Wealth Management LLC raised its stake in Global X Genomics & Biotechnology ETF by 12.1% during the second quarter. Oxinas Partners Wealth Management LLC now owns 16,212 shares of the company’s stock worth $137,000 after acquiring an additional 1,751 shares in the last quarter. HighTower Advisors LLC increased its position in Global X Genomics & Biotechnology ETF by 16.7% in the first quarter. HighTower Advisors LLC now owns 15,242 shares of the company’s stock worth $121,000 after purchasing an additional 2,184 shares during the period. Smartleaf Asset Management LLC lifted its stake in shares of Global X Genomics & Biotechnology ETF by 18.5% in the 1st quarter. Smartleaf Asset Management LLC now owns 14,933 shares of the company’s stock valued at $125,000 after purchasing an additional 2,329 shares during the period. Private Advisor Group LLC grew its position in shares of Global X Genomics & Biotechnology ETF by 14.3% during the 1st quarter. Private Advisor Group LLC now owns 20,738 shares of the company’s stock worth $165,000 after buying an additional 2,587 shares during the period. Finally, Manhattan West Asset Management LLC grew its position in shares of Global X Genomics & Biotechnology ETF by 13.0% during the 1st quarter. Manhattan West Asset Management LLC now owns 29,947 shares of the company’s stock worth $238,000 after buying an additional 3,439 shares during the period. 56.95% of the stock is owned by institutional investors.

Global X Genomics & Biotechnology ETF Trading Up 2.2%

Global X Genomics & Biotechnology ETF stock opened at $45.45 on Friday. The firm has a market capitalization of $55.45 million, a P/E ratio of -19.42 and a beta of 1.22. Global X Genomics & Biotechnology ETF has a 1 year low of $27.20 and a 1 year high of $45.47. The business has a 50-day moving average of $39.72 and a 200-day moving average of $35.60.

Global X Genomics & Biotechnology ETF Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.